Jens Marquardt

[Jens Marquardt @jumarquardt]

Herzliche Einladung zu unserem 4. Ostseesymposium der Viszeralonkologie!

https://t.co/OOckKEiH0X

[Jens Marquardt @jumarquardt]

Great work by @LichunMa and @XinWang77 dissecting intratumoral heterogeneity of primary liver cancer https://t.co/oGwht5viBr

[Jens Marquardt @jumarquardt]

Liver Cancer Summit 2022 https://t.co/OiOAIE83WD

[Jens Marquardt @jumarquardt]

#ascogi22 Great presentation by Augusto Villanueva @augustoNYC and many others on primary liver cancer. Practice Changing results from TOPAZ-1 in #BiliaryTractCancer and HIMALAYA #HCC later today.

[Jens Marquardt @jumarquardt]

Outstanding work by Dr. Czauderna highlighting the importance of early epigenetic alterations in HCC. Thanks to everybody for the great contribution @jaboeje @ColmJJORourke https://t.co/NHOJO4dxKC

[Incyte @Incyte]

#News: The @EU_Commission has granted approval for a new treatment for adults with locally advanced or metastatic #cholangiocarcinoma with FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

[Jens Marquardt @jumarquardt]

The co‐mutational spectrum determines the therapeutic response in murine FGFR2 fusion ‐ driven cholangiocarcinoma https://t.co/rKfY3kGdIM

[Jens Marquardt @jumarquardt]

p53-independent induction of p21 fails to control regeneration and hepatocarcinogenesis in a murine liver injury model https://t.co/6MwtYoHKri

[Jens Marquardt @jumarquardt]

I will be a participant at Digital #LiverCancerSummit 2021. Join me there to discuss the latest knowledge on #livercancer. Together we are stronger against liver cancer. Find out more about the event: https://t.co/8glWYrzbDj @EASLnews